Scientist / Senior Scientist, Peptide Discovery

Basecamp Research is building frontier AI for therapeutic design. We believe the future of medicine lies in reprogramming the body to repair itself, and we design the models and the medicines to teach it how. Our EDEN models are trained on BaseData, the world's largest proprietary genomic dataset, with over 10B genes collected through partnerships in more than 30 countries across all seven continents. This gives our AI models access to genetic diversity that doesn't exist in public databases, and enables EDEN to design cell and gene therapies, enzymes, and peptides directly from information about a disease. Our pipeline of EDEN-designed therapeutics, beginning with in vivo cell therapy, is advancing towards clinical development. In September 2026 we closed an oversubscribed $140M Series C led by S32, with participation from NVIDIA, Anthropic's Anthology Fund, Catalio, European Tech Collective, Firebrand River Capital, King Philanthropies, NATO Innovation Fund, NVentures (NVIDIA's venture arm), Redalpine, Rockefeller Foundation, Singular, Sovereign AI and True Ventures. We have offices and labs in London and Boston, we partner with biopharma companies and academic institutions worldwide, and our work has been recognised by Fast Company's Top 10 Most Innovative Companies in Biotech, the FT-backed Sifted AI100 list of Europe's leading AI startups as well as Barclays Eagle Labs Ones to watch, AI100. At Basecamp Research, we pride ourselves on being a lean collaborative and global team with extremely specialist and unique skills. Our biologists, engineers, ML scientists and field explorers are united by a sense of adventure and the belief that AI, biology and data, will result in new medicines for patients who have few options today.

We are seeking a highly capable and proactive Scientist / Senior Scientist, Peptide Discovery to join our Boston, MA team. This role reports to the Head of Gene Editing and Early Discovery and supports the experimental validation of AI-generated peptide candidates across multiple therapeutic programs — including but not limited to antifungal, antimicrobial, and cardiometabolic peptides — through cell culture-based functional, safety, and developability assays that directly inform our AI-guided peptide discovery pipeline.

Mammalian cell culture: Perform routine mammalian cell culture (e.g., HepG2, HEK293, CHO, or receptor-expressing stable cell lines). Cytotoxicity/viability assays: Design and execute cell-based cytotoxicity/viability assays (e.g., CellTiter Blue or equivalent) in 96-well format. Hemolysis assays: Run hemolysis assays using red blood cells to assess membrane-disruptive toxicity of peptide candidates. Cell permeability assays: Run cell permeability assays to evaluate peptide membrane interaction and barrier penetration. Immunogenicity risk assessment: Support immunogenicity risk assessment of peptide candidates, which may include in silico T-cell epitope prediction, PBMC-based cytokine release or proliferation assays. GLP-1R activation assays: Run cell-based receptor activation assays for GLP-1 and related incretin peptide candidates, including cAMP accumulation assays (e.g., HTRF, ELISA-based, or luciferase reporter formats) in GLP-1R-expressing stable cell lines. Stable cell line support: Support or help establish stable reporter/receptor cell lines (e.g., transfection, antibiotic selection, flow cytometry-based confirmation of receptor expression) for new peptide target classes. Dose-response analysis: Generate and fit dose-response curves for potency (EC50) and safety (LC50, hemolytic/cytotoxic thresholds) endpoints. Peptide handling: Prepare peptide stock and working solutions from synthesized peptides (crude and high-purity formulations) for cell-based testing. Fungal susceptibility support: Support MIC-style fungal susceptibility assays (e.g., against Saccharomyces cerevisiae , Candida albicans , Candida auris , and Fusarium graminearum